[go: up one dir, main page]

PE20060319A1 - Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona - Google Patents

Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona

Info

Publication number
PE20060319A1
PE20060319A1 PE2005000597A PE2005000597A PE20060319A1 PE 20060319 A1 PE20060319 A1 PE 20060319A1 PE 2005000597 A PE2005000597 A PE 2005000597A PE 2005000597 A PE2005000597 A PE 2005000597A PE 20060319 A1 PE20060319 A1 PE 20060319A1
Authority
PE
Peru
Prior art keywords
ethinylestradiol
chlormadinone acetate
combination
equal
less
Prior art date
Application number
PE2005000597A
Other languages
English (en)
Inventor
Johannes Bartholomaus
Janine Klose
Georg Schramm
Klaus-Michael Wilsmann
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20060319A1 publication Critical patent/PE20060319A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA DE ADMINISTRACION ORAL QUE COMPRENDE: A) DE 21-25 UNIDADES DIARIAS DE UNA COMBINACION DE ETINILESTRADIOL EN IGUAL CANTIDAD O MENOR DE 25ug Y ACETATO DE CLORMADINONA EN CANTIDAD IGUAL O MENOR DE 5 mg; B) DE 7 A 3 UNIDADES DIARIAS QUE NO CONTIENEN HORMONAS. UNA FORMULACION QUE CONTIENE HORMONAS COMPRENDE: 20ug DE ETINILESTRADIOL Y 2mg DE ACETATO DE CLORMADINONA; Y UNA FORMULACION QUE NO CONTIENE HORMONA COMPRENDE: 3mg DE POVIDONA K30; LACTOSA 32mg; FECULA DE MAIZ 12mg; ESTEARATO DE MAGNESIO 0,5mg; DIOXIDO DE SILICIO ALTAMENTE DISPERSO 0,5mg. EL EMPLEO DE ACETATO DE CLORMADINONA GARANTIZA UNA SEGURIDAD ANTICONCEPTIVA ELEVADA Y SE CARACTERIZA POR SUS MARCADAS PROPIEDADES ANTIANDROGENAS, SIENDO UTILES PARA LA ANTICONCEPCION
PE2005000597A 2004-05-28 2005-05-27 Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona PE20060319A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004026670A DE102004026670A1 (de) 2004-05-28 2004-05-28 Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat

Publications (1)

Publication Number Publication Date
PE20060319A1 true PE20060319A1 (es) 2006-06-15

Family

ID=34970113

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000597A PE20060319A1 (es) 2004-05-28 2005-05-27 Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona

Country Status (8)

Country Link
US (1) US9278072B2 (es)
EP (1) EP1753408B1 (es)
AR (1) AR049197A1 (es)
DE (1) DE102004026670A1 (es)
ES (1) ES2718636T3 (es)
HU (1) HUE043200T2 (es)
PE (1) PE20060319A1 (es)
WO (1) WO2005115351A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
US20090117184A1 (en) * 2007-11-05 2009-05-07 Sabine Fricke Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception
DE202007019049U1 (de) * 2007-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Verwendung eines Gestagens in Kombination mit einem Estrogen zur Prophylaxe der Laktoseintoleranz bei der oralen Kontrazeption
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
PL3106148T3 (pl) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy
CN107810001A (zh) 2015-06-18 2018-03-16 密特拉制药公司 含雌四醇的口腔分散片剂
CA2988362C (en) 2015-06-18 2022-07-19 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
CN107787224A (zh) 2015-06-18 2018-03-09 密特拉制药公司 含雌四醇组分的口腔分散剂量单位
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4635051A (en) 1983-09-26 1987-01-06 Tektronix, Inc. High-speed electro-optical light gate and field sequential full color display system incorporating same
AU4805085A (en) 1984-09-05 1986-03-24 Schering Aktiengesellschaft Mittel zur behandlung von androgenisierungserscheinungen und verwendung von antiandrogenen zur herstellung des mittels
DK174724B1 (da) 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE4104385C1 (es) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (de) * 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4308406C1 (de) * 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
DE4339934C2 (de) 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4321957C2 (de) 1993-07-01 1995-09-28 Marika Dr Med Ehrlich Verwendung eines hormonalen Mittels zur Therapie der Akne
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19539233A1 (de) 1995-10-21 1997-04-24 Klaus Dr Med Umbreit Oral einzunehmendes ovulationshemmendes Mittel
US6511970B1 (en) * 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
DE19705229C2 (de) * 1997-02-12 1999-04-15 Hesch Rolf Dieter Prof Dr Med Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6326392B1 (en) * 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
AU3567699A (en) * 1998-04-17 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
US8048869B2 (en) 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
PT1293210E (pt) * 2001-05-23 2004-04-30 Pantarhei Bioscience Bv Dispositivo e metodo anticoncepcional hormonal
AU2003256430A1 (en) * 2002-08-15 2004-03-03 Wyeth AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
JP2006525358A (ja) 2003-05-02 2006-11-09 ドゥラメド ファーマシューティカルズ， インコーポレイテッド 長期周期避妊養生法を利用するホルモン治療の方法

Also Published As

Publication number Publication date
AR049197A1 (es) 2006-07-05
US9278072B2 (en) 2016-03-08
US20050267084A1 (en) 2005-12-01
HUE043200T2 (hu) 2019-08-28
WO2005115351A1 (de) 2005-12-08
DE102004026670A1 (de) 2005-12-15
EP1753408B1 (de) 2019-01-02
EP1753408A1 (de) 2007-02-21
ES2718636T3 (es) 2019-07-03

Similar Documents

Publication Publication Date Title
PE20060319A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
AR097341A2 (es) Composición farmaceutica que comprende una dispersión de macrólidos sólidos, y un proceso para producir una tableta dispersable que contiene un macrólido
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
HUP0303182A2 (hu) Gyógyászati készítmények
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2007048219A3 (en) Sustained drug release composition
NO20064473L (no) Stabilised supersaturated solid solutions of steroidal drugs
BRPI0408396A (pt) pelìculas de dissolução rápida, consumìveis por via oral, contendo agentes farmaceuticamente ativos
HUP0401714A2 (hu) Propiverin vagy gyógyászatilag elfogadható sóinak nyújtott hatóanyag-eladású, orális adagolási formái
EE9900288A (et) Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks
CL2009002187A1 (es) Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06).
BR0213288A (pt) Etilcelulose altamente compressìvel para formação de comprimidos
PE20130524A1 (es) Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosis
PE20110573A1 (es) Sistema de administracion de drogas que contiene progestina
MY157790A (en) Trazodone composition for once a day administration
TW200633730A (en) Oral disintegrating dosage forms
MX2022012917A (es) Composiciones anticonceptivas con efectos adversos reducidos.
CL2007001961A1 (es) Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.
AP2004003046A0 (en) Dosage regimen and pharmaceutical composition for emergency contraception.
PE20070208A1 (es) Anticoncepcion oral con trimegestona
BRPI0512993A (pt) uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto
ES2130081B1 (es) Comprimido de maleato de trimebutina con recubrimiento laminar.
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
IL166432A0 (en) Composition containing an androgenous 11?-halogen steroid and a progestational hormone and male contraceptive based on said composition

Legal Events

Date Code Title Description
FC Refusal